10/03/2025
When Herriot Tabuteau started a drug development company in 2012, he decided to do so differently. First, he’d focus on brain disorders, treatments for which are notoriously difficult to develop and whose efficacy can be hard to prove. And he’d be both CEO and the scientific founder, bringing to bear his decÂades of experience investing in biotech startups and his medical training. But he’d take no venture capital, self-funding with help from friends and family.
Named for two parts of a nerve cell, the “axon” and the “soma,” Axsome has come a long way from its beginnings in a windowless three-desk office in New York’s Rockefeller Center, affectionately remembered as “the broom closet.”
Today, it has three drugs on the market and five in the pipeline, with the potential to help the estimated 150 million Americans suffering from conditions like depression, ADHD or Alzheimer’s disease.
Continue reading: https://bit.ly/4ntB8iy
(Photo: Jamel Toppin for Forbes)
